Washington University in St. Louis

Washington University Open Scholarship
Volume 12

Washington University
Undergraduate Research Digest

Spring 2017

Pathological Biomarkers and Cognitive Change in Parkinson
Disease
Alexandra J. Weigand
Washington University in St. Louis

Follow this and additional works at: https://openscholarship.wustl.edu/wuurd_vol12

Recommended Citation
Weigand, Alexandra J., "Pathological Biomarkers and Cognitive Change in Parkinson Disease" (2017).
Volume 12. 207.
https://openscholarship.wustl.edu/wuurd_vol12/207

This Abstracts S-Z is brought to you for free and open access by the Washington University
Undergraduate Research Digest at Washington University Open Scholarship. It has been accepted for inclusion in
Volume 12 by an authorized administrator of Washington University Open Scholarship. For more information,
please contact digital@wumail.wustl.edu.

Toward a Better Understanding of...

Pathological Biomarkers and Cognitive
Change in Parkinson Disease
Alexandra J. Weigand
Mentor: Meghan Campbell
Although Parkinson disease (PD) is primarily considered a movement disorder, there are
also cognitive problems associated with this disorder that cause significant impairment
to quality of life. There is, however, a high degree of inter-individual variability in
cognitive dysfunction in PD, necessitating prognostic tools that can predict the
trajectory of cognitive decline for a given individual. The current study investigates the
utility of various biomarkers associated with the pathological progression of PD and
their ability to predict cognitive change across different domains and time intervals.
Data were obtained for 174 PD participants who were either cognitively normal (N =
93) or cognitively impaired (N = 81) at baseline. Regression analyses were conducted to
determine associations between baseline biomarkers (including cerebrospinal fluid (CSF)
amyloid-beta 1-42 (Aβ1-42), tau, and alpha-synuclein (α-syn); amyloid-beta deposition
measured with Pittsburgh compound B (PiB); and regional gray matter volumes
(GMV)) and reliable change indices (RCIs) for five cognitive domains across one, two,
and three year intervals. Results indicated that CSF and PiB measures of amyloid-beta
pathology predicted cognitive change across longer time intervals, whereas regional
GMVs predicted more imminent cognitive change. Further, the timing of cognitive
change varied based on the location of amyloid-beta deposition such that brainstem
and posterior cortical amyloid-beta deposition was predictive of distant future cognitive
change and anterior cortical amyloid-beta deposition was predictive of more imminent
cognitive change, suggesting that amyloid pathology follows a caudo-rostral progression
similar to Lewy body pathology in PD. These findings may have prognostic value, such
that the presence of certain biomarkers and the location of pathology may predict which
PD patients will develop cognitive impairment and when the decline will begin.

246

